C1 inhibitor Proteins, Antibodies, cDNA Clones, ELISA Kits Research Reagents

SERPING1 (Serpin Family G Member 1) is a protein coding gene located on human chromosome 11q12.1. SERPING1 is also known as C1IN, C1NH, HAE1, HAE2, and C1INH. The human SERPING1 gene encodes a 55154 Da protein containing 500 amino acids. The SERPING1 protein is broadly expressed in liver, gall bladder and other tissues. Among its related pathways are Formation of Fibrin Clot (Clotting Cascade) and Cell adhesion_Plasmin signaling. SERPING1 is related to serine-type endopeptidase inhibitor activity. SERPINF2 is an important paralog of SERPING1 gene. SERPING1 is associated with some diseases, including Angioedema, Hereditary, Type I and Complement Component 4, Partial Deficiency Of.

C1 inhibitor Protein (2)

    C1 inhibitor Antibody (6)

      C1 inhibitor ELISA Kit & Match Antibody ELISA Pair Set (2)

      C1 inhibitor cDNA Clone (52)


      C1 inhibitor qPCR Primer (1)

      C1 inhibitor Lysate (2)

        More Product Popular With Customers

        C1 inhibitor Background

        Plasma protease C1 inhibitor, also known as C1-inhibiting factor, C1-INH, C1 esterase inhibitor, SERPING1 and C1IN, is a serine proteinase inhibitor (serpin) that regulates activation of both the complement and contact systems. By its C-terminal part (serpin domain), characterized by three beta-sheets and an exposed mobile reactive loop, C1-INH binds, and blocks the activity of its target proteases. The N-terminal end (nonserpin domain) confers to C1-INH the capacity to bind lipopolysaccharides and E-selectin. Owing to this moiety, C1-INH intervenes in regulation of the inflammatory reaction. The heterozygous deficiency of C1-INH results in hereditary angioedema (HAE). Owing to its ability to modulate the contact and complement systems and the convincing safety profile, plasma-derived C1 inhibitor is an attractive therapeutic protein to treat inflammatory diseases other than HAE. Deficiency of C1 inhibitor results in hereditary angioedema, which is characterized by recurrent episodes of localized angioedema of the skin, gastrointestinal mucosa or upper respiratory mucosa. C1 inhibitor may prove useful in a variety of other diseases including septic shock, reperfusion injury, hyperacute transplant rejection, traumatic and hemorrhagic shock, and the increased vascular permeability associated with thermal injury, interleukin-2 therapy and cardiopulmonary bypass.

        C1 inhibitor References

        • Davis AE 3rd. et al. (2004) Biological effects of C1 inhibitor. Drug News Perspect. 17(7): 439-46.
        • Cicardi M, et al. (2005) C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol. 27(3): 286-98.
        • Wouters D, et al. (2008) C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther. 8(8): 1225-40.
        • Cugno M, et al. (2009) C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 15(2): 69-78.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.